EZH2 and cancer: It should also be noted that evasion of the viral mimicry response is an acquired characteristic of certain cancers, such as acute myeloid leukemia (via SETDB1) [12] and treatment-resistant triple-negative breast cancer (via EZH2) [13], thus evoking new therapeutic vulnerabilities in these malignancies.